Parvez Mantry, MD
Gastroenterology · Dallas, TXNPI 1770528697
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $621,902 of the $958,425 with a category attached, or 64.9%. It is spread thinly across 45 manufacturers, the largest accounting for just 20.8%. 2025 is the largest year on record at $302,443, 2.5 times the $122,610 reported in 2019. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,052 payments — averaging $911.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$199K
- Madrigal Pharmaceuticals$154K
- Gilead$121K
- Intercept Pharmaceuticals, Inc.$105K
- Eisai Inc.$97K
- AbbVie$90K
- plus $192K from 39 others
Across 1,604 payments — averaging $3371.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.6M
- Intercept Pharmaceuticals, Inc.$1.2M
- AbbVie$593K
- Sirtex Medical Inc$388K
- Genentech, Inc.$339K
- E.r. Squibb & Sons, L.L.C.$204K
- plus $1.1M from 16 others
What the payments were for
- Consulting fees$240,13125%
- Speaking & faculty fees$621,90265%
- Travel & lodging$65,1557%
- Food & beverage$31,1973%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$152,600
- OCALIVA$103,517
- LENVIMA$96,697
- Mavyret$87,033
- Vemlidy$50,730
- Livdelzi$44,497
- UPLIZNA$38,184
- XIFAXAN$37,495
- IQIRVO$31,016
- Wegovy$30,502
- SIR-Spheres Microspheres$20,624
- Mulpleta$12,984
- DOPTELET$9,272
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$8,500
- VIATORR Endoprosthesis$8,250
- Epclusa$7,657
- SIMPONI ARIA$4,131
- STELARA$4,131
- THERASPHERE$3,250
- CUVRIOR$3,149
How this compares
$958,425 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 41 | $959,956 |
| XifaxanRifaximin | 130 | $394,299 |
| OcalivaObeticholic Acid | 40 | $377,133 |
| RezdiffraResmetirom | 64 | $276,916 |
| VemlidyTenofovir Alafenamide | 81 | $119,038 |
| OzempicSemaglutide | 54 | $51,905 |
| Ursodiol | 269 | $39,749 |
| Tacrolimus | 274 | $26,020 |
| Sirolimus | 30 | $8,258 |
| Mycophenolate Mofetil | 122 | $6,424 |
| Entecavir | 50 | $3,510 |
| Mycophenolic AcidMycophenolate Sodium | 13 | $2,565 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 37 | $2,267 |
| Lactulose | 47 | $1,833 |
| Spironolactone | 167 | $1,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $121,388 | $1,078,994122 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $38,708 | $394,299130 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $105,173 | $377,13340 claims |
| Madrigal PharmaceuticalsRezdiffra | $153,856 | $276,91664 claims |
| Novo NordiskOzempic | $199,075 | $51,90554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Dallas
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Jay HortonDallas$326K
- Jacqueline O LearyDallas$157K
- Sami ArslanlarDallas$142K
- Amit DesaiDallas$71K
- Byron CryerDallas$68K
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.